Compare UNB & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNB | KRRO |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 139.0M |
| IPO Year | 1999 | 2019 |
| Metric | UNB | KRRO |
|---|---|---|
| Price | $23.04 | $11.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | 2.2K | ★ 163.0K |
| Earning Date | 10-21-2026 | 11-11-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | ★ 25.52 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $56.67 |
| P/E Ratio | $18.44 | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $20.65 | $5.20 |
| 52 Week High | $26.41 | $42.70 |
| Indicator | UNB | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 63.86 |
| Support Level | $22.89 | $10.18 |
| Resistance Level | $24.16 | $12.54 |
| Average True Range (ATR) | 0.36 | 1.00 |
| MACD | 0.03 | 0.38 |
| Stochastic Oscillator | 33.99 | 97.35 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.